GGrantIndex
Sort

78,016 grants matching breast cancer

PENN RCMAR

$623,665
Jerry Calvin Johnson · University Of Pennsylvania · P30 · FY2009 · AG

Epidemiology of Molecular Risk Factors for Breast Cancer

$623,660
William D Dupont · Vanderbilt University · R01 · FY2007 · CA

Multi-site adaptive trial of a technology-based, EHR-integrated physical activity intervention in breast and endometrial cancer survivors

$623,601
Siobhan Marie Phillips · Northwestern University At Chicago · R37 · FY2025 · CA

Alliance for Clinical Trials in Oncology Operations Center - GY11 BIQSFP Funded Extension

$623,526
Steven Piantadosi · Brigham And Women'S Hospital · U10 · FY2025 · CA

NEXT-GENERATION MOLECULAR HISTOLOGY USING HIGHLY MULTIPLEXED ION-BEAM IMAGING (MIBI) OF BREAST CANCER TISSUE SPECIMENS FOR ENHANCED CLINICAL GUIDANCE

$623,524
University Of California, Davis · · FY2014 · Department of the Army

(PQC2)High-content Pathology with Confocal Microscope Arrays

$623,480
Christopher H Contag · Stanford University · R01 · FY2014 · CA

Protein and proteolytic activity biomarkers of early stage pancreatic cancer

$623,472
Paul Tempst · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA

Protein and proteolytic activity biomarkers of early stage pancreatic cancer

$623,472
Paul Tempst · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Acceptance and Commitment Therapy for Fear of Recurrence in Breast Cancer Survivors

$623,355
Shelley A. Johns · Indiana University Indianapolis · R01 · FY2023 · CA

Impact of Affect Reactivity and Regulation on Breast Cancer Treatment Decisions

$623,354
David Spiegel · Stanford University · U01 · FY2016 · CA

Research Program

$623,251
Alison Meredith Buttenheim · University Of Pennsylvania · P50 · FY2023 · CA

A nested case-control study of perfluoroalkyl and polyfluoroalkyl substances (PFAS) and breast cancer risk in the Multiethnic Cohort

$623,229
Eunjung Lee · University Of Southern California · R01 · FY2024 · CA

Long-Term Trajectories of Accelerated Biological Aging and Functional Decline Associated with Breast Cancer and its Treatment

$623,178
Elizabeth Marjorie Cespedes Feliciano · Kaiser Foundation Research Institute · R01 · FY2024 · CA

Identifying Diagnostic Markers for Cervical, Breast, and Prostate Cancer

$623,145
Thomas Ried · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Digital Pathology_Accuracy Viewing Behavior and Image Characterization

$623,127
Joann G Elmore · University Of Washington · R01 · FY2014 · CA

Functional Determinants of Metastatic Dormancy

$623,104
Julio A Aguirre-Ghiso · Albert Einstein College Of Medicine · R01 · FY2023 · CA

Functional Determinants of Metastatic Dormancy

$623,104
Julio A Aguirre-Ghiso · Albert Einstein College Of Medicine · R01 · FY2025 · CA

Biomarkers and Breast Cancer Risk Prediction in Younger Women

$623,103
Anne Zeleniuch-Jacquotte · New York University School Of Medicine · R01 · FY2014 · CA

Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation with Movement to Improve Prognosis in Breast Cancer Survivors

$623,101
Christina Dieli-Conwright · Dana-Farber Cancer Inst · R01 · FY2022 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIES

$623,064
University Of Wisconsin Madison · U10 · FY2003 · CA

Atlanta Regional Community Clinical Oncology Program

$623,000
Thomas E Seay · St. Joseph'S Hospital · U10 · FY2007 · CA

Optimizing Individualized and Adaptive mHealth Interventions via Control Systems Engineering Methods

$622,967
Eric Hekler · University Of California, San Diego · R01 · FY2023 · CA

OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY

$622,961
Gregory M Lanza · Washington University · R01 · FY2021 · CA

OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY

$622,961
Gregory M Lanza · Washington University · R01 · FY2018 · CA

OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY

$622,961
Gregory M Lanza · Washington University · R01 · FY2020 · CA